Intensity Therapeutics Reports FY Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy INTS?
Source: seekingalpha
- Disappointing Earnings: Intensity Therapeutics reported a FY GAAP EPS of -$8.56, missing expectations by $0.69, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $11.9 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction Outlook: Given the earnings miss, the stock price of Intensity Therapeutics is expected to face downward pressure, prompting investors to reassess the company's growth potential and associated risks.
- Analyst Rating Focus: Increased market attention on Intensity Therapeutics is likely, with Seeking Alpha's Quant Rating serving as a critical reference for investors evaluating the company's outlook, especially in light of its current financial struggles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INTS
Wall Street analysts forecast INTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.030
Low
1.50
Averages
3.33
High
5.00
Current: 6.030
Low
1.50
Averages
3.33
High
5.00
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intensity Therapeutics Reports FY Losses
- Disappointing Earnings: Intensity Therapeutics reported a FY GAAP EPS of -$8.56, missing expectations by $0.69, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $11.9 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction Outlook: Given the earnings miss, the stock price of Intensity Therapeutics is expected to face downward pressure, prompting investors to reassess the company's growth potential and associated risks.
- Analyst Rating Focus: Increased market attention on Intensity Therapeutics is likely, with Seeking Alpha's Quant Rating serving as a critical reference for investors evaluating the company's outlook, especially in light of its current financial struggles.
See More
Intensity Therapeutics Reports 2025 Year-End Financial Results and Corporate Update
- Financial Improvement: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million, extending its operating runway into Q2 2027, indicating positive progress in capital raising efforts.
- Clinical Trial Progress: The INVINCIBLE-3 study paused new patient enrollments due to funding constraints but had enrolled 21 patients and continues treatment, with plans to resume enrollment in 2026, demonstrating the company's ongoing commitment to clinical research.
- Reduced R&D Expenses: Research and development expenses for 2025 were $6.8 million, down from $10.5 million in 2024, primarily due to lower costs associated with the INVINCIBLE-3 study, reflecting effective cost control measures by the company.
- Decreased Net Loss: The net loss for 2025 was $11.6 million, compared to $16.3 million in 2024, indicating improvements in financial management and operational efficiency.
See More
Intensity Therapeutics Reports 2025 Financial Results and Study Updates
- Capital Raising Success: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million as of December 31, 2025, which extends the company's operational runway into the second quarter of 2027, thereby enhancing financial stability.
- Clinical Study Results: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of early-stage triple-negative breast cancer patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the control group, indicating the potential efficacy of INT230-6 and its ability to change treatment standards.
- Safety Analysis: The INVINCIBLE-4 study observed a 44% reduction in grade 3 or higher adverse events among patients receiving INT230-6, suggesting a significant safety advantage for this treatment regimen, which may enhance patient compliance.
- Published Research Impact: Results from the IT-01 study of INT230-6 were published in eBioMedicine, showing a 75% disease control rate and a median overall survival of 11.9 months in 64 heavily pretreated patients, surpassing historical data and emphasizing the therapy's potential in treating metastatic cancers.
See More
Intensity Therapeutics Inc. Expands ATM Facility to Improve Financial Flexibility, According to SEC Filing
Facility Expansion: The INTENSITY Therapeutics facility has been expanded to enhance its capabilities.
Financial Flexibility: The expansion aims to improve financial flexibility for the organization.
See More
Intensity Therapeutics Inc. Plans to Offer Up to $60 Million in Common Stock, According to SEC Filing
Financial Overview: Intensity Therapeutics is facing a significant financial challenge, with a potential loss of up to $60 million in common stock under an offering agreement.
Filing Details: The company is in the process of filing a SEC document related to this offering, indicating a strategic move to manage its financial situation.
See More
Intensity Therapeutics Updates on INVINCIBLE-4 Study Progress
- Clinical Trial Progress: Intensity Therapeutics has treated 14 patients in the INVINCIBLE-4 study, with total enrollment expected to reach 61, indicating the company's proactive exploration in early-stage triple-negative breast cancer treatment.
- Efficacy Observations: Preliminary data shows that 71.4% (5/7) of patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2/6) in the SOC arm, highlighting the potential advantages of INT230-6.
- Safety Data: Safety data for patients receiving INT230-6 plus SOC remain favorable compared to SOC alone, with management noting a 44% reduction in grade 3 or higher adverse events, which could be life-saving for patients.
- Stock Split and Market Performance: The company recently executed a 1-for-25 reverse stock split to increase the per-share trading price, although the stock price fell 6.70% to $7.50 at publication, reflecting market attention on its clinical trials and potential growth opportunities.
See More
Intensity Therapeutics Reports FY Losses
- Disappointing Earnings: Intensity Therapeutics reported a FY GAAP EPS of -$8.56, missing expectations by $0.69, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $11.9 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction Outlook: Given the earnings miss, the stock price of Intensity Therapeutics is expected to face downward pressure, prompting investors to reassess the company's growth potential and associated risks.
- Analyst Rating Focus: Increased market attention on Intensity Therapeutics is likely, with Seeking Alpha's Quant Rating serving as a critical reference for investors evaluating the company's outlook, especially in light of its current financial struggles.
See More
Intensity Therapeutics Reports 2025 Year-End Financial Results and Corporate Update
- Financial Improvement: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million, extending its operating runway into Q2 2027, indicating positive progress in capital raising efforts.
- Clinical Trial Progress: The INVINCIBLE-3 study paused new patient enrollments due to funding constraints but had enrolled 21 patients and continues treatment, with plans to resume enrollment in 2026, demonstrating the company's ongoing commitment to clinical research.
- Reduced R&D Expenses: Research and development expenses for 2025 were $6.8 million, down from $10.5 million in 2024, primarily due to lower costs associated with the INVINCIBLE-3 study, reflecting effective cost control measures by the company.
- Decreased Net Loss: The net loss for 2025 was $11.6 million, compared to $16.3 million in 2024, indicating improvements in financial management and operational efficiency.
See More
Intensity Therapeutics Reports 2025 Financial Results and Study Updates
- Capital Raising Success: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million as of December 31, 2025, which extends the company's operational runway into the second quarter of 2027, thereby enhancing financial stability.
- Clinical Study Results: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of early-stage triple-negative breast cancer patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the control group, indicating the potential efficacy of INT230-6 and its ability to change treatment standards.
- Safety Analysis: The INVINCIBLE-4 study observed a 44% reduction in grade 3 or higher adverse events among patients receiving INT230-6, suggesting a significant safety advantage for this treatment regimen, which may enhance patient compliance.
- Published Research Impact: Results from the IT-01 study of INT230-6 were published in eBioMedicine, showing a 75% disease control rate and a median overall survival of 11.9 months in 64 heavily pretreated patients, surpassing historical data and emphasizing the therapy's potential in treating metastatic cancers.
See More
Intensity Therapeutics Inc. Expands ATM Facility to Improve Financial Flexibility, According to SEC Filing
Facility Expansion: The INTENSITY Therapeutics facility has been expanded to enhance its capabilities.
Financial Flexibility: The expansion aims to improve financial flexibility for the organization.
See More
Intensity Therapeutics Inc. Plans to Offer Up to $60 Million in Common Stock, According to SEC Filing
Financial Overview: Intensity Therapeutics is facing a significant financial challenge, with a potential loss of up to $60 million in common stock under an offering agreement.
Filing Details: The company is in the process of filing a SEC document related to this offering, indicating a strategic move to manage its financial situation.
See More
Intensity Therapeutics Updates on INVINCIBLE-4 Study Progress
- Clinical Trial Progress: Intensity Therapeutics has treated 14 patients in the INVINCIBLE-4 study, with total enrollment expected to reach 61, indicating the company's proactive exploration in early-stage triple-negative breast cancer treatment.
- Efficacy Observations: Preliminary data shows that 71.4% (5/7) of patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2/6) in the SOC arm, highlighting the potential advantages of INT230-6.
- Safety Data: Safety data for patients receiving INT230-6 plus SOC remain favorable compared to SOC alone, with management noting a 44% reduction in grade 3 or higher adverse events, which could be life-saving for patients.
- Stock Split and Market Performance: The company recently executed a 1-for-25 reverse stock split to increase the per-share trading price, although the stock price fell 6.70% to $7.50 at publication, reflecting market attention on its clinical trials and potential growth opportunities.
See More
